TY - JOUR
T1 - Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin
AU - Bilen, Mehmet Asim
AU - Cauley, Diana H.
AU - Atkinson, Bradley J.
AU - Chen, Hsiang Chun
AU - Kaya, Diana H.
AU - Wang, Xuemei
AU - Vikram, Raghu
AU - Tu, Shi Ming
AU - Corn, Paul G.
AU - Kim, Jeri
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2017/6
Y1 - 2017/6
N2 - Although myeloid growth factors are commonly used to treat metastatic castration-resistant prostate cancer, the optimal timing of administration has not been well studied. We demonstrate that same-day pegfilgrastim administration after cabazitaxel treatment with or without carboplatin in patients with metastatic castration-resistant prostate cancer is feasible. Furthermore, we observed that the rate of urinary tract inflammation was higher than that reported anecdotally. Introduction Although myeloid growth factors are commonly used to treat metastatic castration-resistant prostate cancer (mCRPC), the optimal timing of administration has not been well studied. We assessed the effects of same-day pegfilgrastim, a neutrophil stimulator, after cabazitaxel treatment with or without carboplatin in patients with mCRPC. We also evaluated the frequency of urinary tract inflammation during treatment. Patients and Methods Between September 2010 and September 2014, 151 consecutive patients with mCRPC underwent cabazitaxel treatment with or without the addition of carboplatin at a single institution. We assessed absolute neutrophil count recovery, incidence of neutropenia, neutropenic fever, antibiotic usage, treatment delays or discontinuation, dose reduction, and hospitalization with pegfilgrastim administration. Radiologists blinded to therapy reviewed computed tomography scans to detect urinary tract inflammation. Results The median patient age was 69 years (range, 41-88 years); 78% of patients were white, and 54% had a Gleason score ≥ 9. Median overall survival was 9 months (95% confidence interval, 8-11 months). One patient (< 1%) had neutropenia; 38 patients (25%) had infection. During cycle 1, a significantly higher proportion of patients receiving pegfilgrastim after 24 hours developed infection than did those receiving pegfilgrastim the same day (26% vs. 6%; P = .01). Conclusion Same-day pegfilgrastim administration after cabazitaxel treatment with or without carboplatin in patients with mCRPC is feasible. The urinary tract inflammation rate (21%) was higher than that reported anecdotally. Results need to be prospectively validated.
AB - Although myeloid growth factors are commonly used to treat metastatic castration-resistant prostate cancer, the optimal timing of administration has not been well studied. We demonstrate that same-day pegfilgrastim administration after cabazitaxel treatment with or without carboplatin in patients with metastatic castration-resistant prostate cancer is feasible. Furthermore, we observed that the rate of urinary tract inflammation was higher than that reported anecdotally. Introduction Although myeloid growth factors are commonly used to treat metastatic castration-resistant prostate cancer (mCRPC), the optimal timing of administration has not been well studied. We assessed the effects of same-day pegfilgrastim, a neutrophil stimulator, after cabazitaxel treatment with or without carboplatin in patients with mCRPC. We also evaluated the frequency of urinary tract inflammation during treatment. Patients and Methods Between September 2010 and September 2014, 151 consecutive patients with mCRPC underwent cabazitaxel treatment with or without the addition of carboplatin at a single institution. We assessed absolute neutrophil count recovery, incidence of neutropenia, neutropenic fever, antibiotic usage, treatment delays or discontinuation, dose reduction, and hospitalization with pegfilgrastim administration. Radiologists blinded to therapy reviewed computed tomography scans to detect urinary tract inflammation. Results The median patient age was 69 years (range, 41-88 years); 78% of patients were white, and 54% had a Gleason score ≥ 9. Median overall survival was 9 months (95% confidence interval, 8-11 months). One patient (< 1%) had neutropenia; 38 patients (25%) had infection. During cycle 1, a significantly higher proportion of patients receiving pegfilgrastim after 24 hours developed infection than did those receiving pegfilgrastim the same day (26% vs. 6%; P = .01). Conclusion Same-day pegfilgrastim administration after cabazitaxel treatment with or without carboplatin in patients with mCRPC is feasible. The urinary tract inflammation rate (21%) was higher than that reported anecdotally. Results need to be prospectively validated.
KW - Anti-VEGF therapy
KW - Cytokine
KW - Kidney cancer
KW - Therapy trends
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=85009264105&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85009264105&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2016.12.003
DO - 10.1016/j.clgc.2016.12.003
M3 - Article
C2 - 28038931
AN - SCOPUS:85009264105
SN - 1558-7673
VL - 15
SP - e429-e435
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 3
ER -